It is possible this reflects a higher prevalence of gastrointestinal symptoms in areas where less prostate specific antigen (PSA) testing is being done, some practices focus more on colorectal cancer than prostate cancer, or this was a type I error. This evidence concerns the gene KLK3 and prostate carcinoma.